EQUITY COMPENSATION PLAN INFORMATION
The following table provides certain information with respect to all of the Company’s equity compensation plans in effect as of December 31,
2021: | | | | | | | | | | | | |
Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options and RSUs(a) | | | Weighted-Average Exercise Price of Outstanding Options(b) | | | Number of Securities Remaining for Issuance under Equity Compensation Plans excluding securities reflected in column (a))(c) | |
Equity compensation plans approved by stockholders(1) | | | 5,705,185 | | | $ | 10.37 | | | | 702,645 | |
Equity compensation plans not approved by stockholders | | | 180,000 | | | $ | 6.68 | | | | 625,000 | |
Total | | | 5,885,185 | | | $ | 10.24 | | | | 1,327,645 | |
2022:Equity compensation plans
| | | | | | | | | |
approved by stockholders(1) | | | 6,924,925 | | | $9.02 | | | 2,384,517 |
Equity compensation plans not
| | | | | | | | | |
approved by stockholders(2) | | | 470,000 | | | $6.80 | | | 380,000 |
Total | | | 7,349,925 | | | $8.86 | | | 2,764,517 |
(1)
| Includes securities issuable under our 2009 Equity Incentive Plan (the “2009 Plan”), our Amended and Restated 2013 Equity Incentive Plan (the “2013 Plan”), our 2021 Inducement Plan (the “2021 Plan”) and our 2013 Employee Stock Purchase Plan (the “ESPP”). The 2013 Plan provides that on the first day of each fiscal year, ending on (and including) January 1, 2026, the number of shares authorized for issuance under the 2013 Plan is automatically increased by a number equal to: (a) 5% of the total number of shares of capital stock outstanding on the last day of the preceding fiscal year; or (b) such lesser number of shares of common stock as is determined by the Board for the applicable year. The 2021 Plan has a maximum award granted for eligible persons of 850,000 shares. The ESPP provides that on January 1st of each year, ending on (and including) January 1, 2026, the number of shares authorized for issuance under the ESPP is automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year; (b) 165,000 shares; or (c) such lesser number of shares of common stock as is determined by the Board for the applicable year. |
2021 (2)
| Includes securities issuable under our 2021 Inducement Plan, which has a maximum award granted for eligible persons of 850,000 shares. |
2022 NON-EMPLOYEE DIRECTOR COMPENSATION
The following table shows for the fiscal year ended December 31,
20212022 certain information with respect to the compensation of all
non-employee directors of the Company:
| | | | | | | | | | | | | | | | |
Name | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(2) | | | Total ($) | |
David Apelian, M.D., Ph.D. | | | 40,000 | | | | 49,950 | | | | 59,540 | | | | 149,490 | |
Thomas Dietz, Ph.D. | | | 152,500 | | | | 49,950 | | | | 119,080 | | | | 321,530 | |
Jeffrey Glenn, M.D., Ph.D. | | | 57,500 | | | | 49,950 | | | | 59,540 | | | | 166,990 | |
Evan Loh, M.D. | | | 60,000 | | | | 49,950 | | | | 59,540 | | | | 169,490 | |
Christine Murray, M.S., R.A.C. | | | 55,000 | | | | 49,950 | | | | 59,540 | | | | 164,490 | |
Kim Sablich, M.B.A(3) | | | 32,582 | | | | | | | | 130,043 | | | | 162,625 | |
Amit K. Sachdev, J.D. | | | 57,500 | | | | 49,950 | | | | 59,540 | | | | 166,990 | |
Thomas Dietz, Ph.D. | | | 170,000 | | | 30,600 | | | 73,980 | | | 274,580 |
Jeffrey Glenn, M.D., Ph.D. | | | 67,000 | | | 30,600 | | | 36,990 | | | 134,590 |
Lisa Kelly-Croswell(4). | | | 22,500 | | | — | | | 158,568 | | | 181,068 |
Evan Loh, M.D. | | | 69,500 | | | 30,600 | | | 36,990 | | | 137,090 |
Christine Murray, M.S., R.A.C. | | | 64,500 | | | 30,600 | | | 36,990 | | | 132,090 |
Kim Sablich, M.B.A | | | 57,000 | | | 30,600 | | | 36,990 | | | 124,590 |
Amit K. Sachdev, J.D. | | | 67,500 | | | 30,600 | | | 36,990 | | | 135,090 |
(1)
| Amounts paid to Dr. Apelian for service as a non-executive director prior to his appointment as Interim Chief Executive Officer are included in the Summary Compensation Table. |
(2)
| The amounts in this column reflect the aggregate grant date fair value of restricted stock units awarded during the year, computed at the grant date in accordance with ASC 718, based on our closing stock price on the date of grant. These amounts do not reflect the actual economic value that may be realized by the non-employee director upon the vesting of the restricted stock units or the sale of the common stock underlying such restricted stock units. As of December 31, 2021,2022, each of our non-employee directors, other than Ms. Kelly-Croswell who did not join the board until July 2022, had 5,0006,000 unvested restricted stock units. |
(2)(3)
| Amounts listed represent the aggregate grant date fair value of option awards granted during 20212022 computed in accordance with ASC 718. Assumptions used in the calculation of these amounts are included in Note 10 to our audited financial statements included in our Annual Report on Form 10-K for the year ended |
29